You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH):近30項在研藥物處於臨牀試驗階段
格隆匯 06-18 17:11

格隆匯6月18日丨君實生物(688180.SH)在互動平台表示,公司的創新研發領域已經從單抗藥物類型擴展至包括小分子藥物、多肽類藥物、抗體藥物偶聯物(ADCs)、雙特異性或多特異性抗體藥物、雙特異性抗體偶聯藥物、融合蛋白、核酸類藥物等更多類型的藥物研發以及癌症、自身免疫性疾病的下一代創新療法探索。公司在研產品管線覆蓋五大治療領域,包括惡性腫瘤、自身免疫系統疾病、慢性代謝類疾病、神經系統類疾病以及感染類疾病。截至目前,公司已有4款商業化藥品(拓益®、君邁康®、民得維®以及君適達®),近30項在研藥物處於臨牀試驗階段,超過20項在研藥物處在臨牀前開發階段。公司核心產品特瑞普利單抗(拓益®)的12項適應症已於中國內地獲批,其中10項適應症已納入國家醫保目錄。目前公司正在加快推進抗BTLA單抗tifcemalimab(代號:TAB004/JS004)、抗IL-17A單抗(代號:JS005)、PD-1單抗皮下注射製劑(代號:JS001sc)、PD-1/VEGF雙特異性抗體(代號:JS207)等後期階段管線的研發和上市申請等工作,並持續探索包括抗Claudin18.2 ADC(代號:JS107)、PI3K-α口服小分子抑制劑(代號:JS105)、CD20/CD3雙特異性抗體(代號:JS203)、抗DKK1單抗(代號:JS015)、EGFR/HER3雙特異性抗體偶聯藥物(代號:JS212)、PD-1/IL-2雙功能性抗體融合蛋白(代號:JS213)等產品在內的早期階段管線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account